Risk Factors for Acute Kidney Injury Induced by Intravenous Polymyxin B in Chinese Patients with Severe Infection

References

• Thomas R, Velaphi S, Ellis S, et al. The use of polymyxins to treat carbapenem resistant infections in neonates and children. Expert Opin Pharmacother. 2019;20(4):415–422. doi:10.1080/14656566.2018.1559817
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kyriakidou M, Voulgaris GL, et al. Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: an evaluation of the current evidence. J Glob Antimicrob Resist. 2021;24:342–359. doi:10.1016/j.jgar.2020.12.026
   PubMed Web of Science ®Google Scholar
• Nguyen M, Joshi SG. Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: a scientific review. J Appl Microbiol. 2021;131(6):2715–2738. doi:10.1111/jam.15130
   PubMed Web of Science ®Google Scholar
• Tilahun M, Kassa Y, Gedefie A, et al. Emerging carbapenem-resistant Enterobacteriaceae infection, its epidemiology and novel treatment options: a review. Infect Drug Resist. 2021;14:4363–4374. doi:10.2147/IDR.S337611
   PubMed Web of Science ®Google Scholar
• Livermore DM, Nicolau DP, Hopkins KL, et al. Carbapenem-resistant enterobacterales, carbapenem resistant organisms, carbapenemase-producing enterobacterales, and carbapenemase-producing organisms: terminology past its “sell-by date” in an era of new antibiotics and regional carbapenemase epidemiology. Clin Infect Dis. 2020;71(7):1776–1782. doi:10.1093/cid/ciaa122
   Web of Science ®Google Scholar
• Willyard C. The drug-resistant bacteria that pose the greatest health threats. Nature. 2017;543(7643):15. doi:10.1038/nature.2017.21550
   PubMed Web of Science ®Google Scholar
• Li J. Reviving polymyxins: achievements, lessons and the road ahead. Adv Exp Med Biol. 2019;1145:1–8. doi:10.1007/978-3-030-16373-0_1
   Web of Science ®Google Scholar
• Soman R, Bakthavatchalam YD, Nadarajan A, et al. Is it time to move away from polymyxins?: evidence and alternatives. Eur J Clin Microbiol Infect Dis. 2021;40(3):461–475. doi:10.1007/s10096-020-04053-w
   Web of Science ®Google Scholar
• Nang SC, Azad MAK, Velkov T, et al. Rescuing the last-line polymyxins: achievements and challenges. Pharmacol Rev. 2021;73(2):679–728. doi:10.1124/pharmrev.120.000020
   PubMed Web of Science ®Google Scholar
• Pogue JM, Ortwine JK, Kaye KS. Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins? Int J Antimicrob Agents. 2016;48(6):622–626. doi:10.1016/j.ijantimicag.2016.11.001
   PubMed Web of Science ®Google Scholar
• Sales GTM, Foresto RD. Drug-induced nephrotoxicity. Rev Assoc Med Bras. 2020;66:s82–s90. doi:10.1590/1806-9282.66.S1.82
   Web of Science ®Google Scholar
• Oliota AF, Penteado ST, Tonin FS, et al. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies. Diagn Microbiol Infect Dis. 2019;94(1):41–49. doi:10.1016/j.diagmicrobio.2018.11.008
   PubMed Web of Science ®Google Scholar
• Pogue JM, Tam VH. Toxicity in patients. Adv Exp Med Biol. 2019;1145:289–304. doi:10.1007/978-3-030-16373-0_17
   Web of Science ®Google Scholar
• Nation RL, Rigatto MHP, Falci DR, et al. Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity. Antibiotics. 2019;8(1):24. doi:10.3390/antibiotics8010024
   Web of Science ®Google Scholar
• Gomes EC, Falci DR, Bergo P, et al. Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery. Int J Antimicrob Agents. 2018;52(1):86–89. doi:10.1016/j.ijantimicag.2018.02.016
   Web of Science ®Google Scholar
• Sisay M, Hagos B, Edessa D, et al. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Pharmacol Res. 2021;163:105328. doi:10.1016/j.phrs.2020.105328
   PubMed Web of Science ®Google Scholar
• Wagenlehner F, Lucenteforte E, Pea F, et al. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins [published online ahead of print]. Clin Microbiol Infect. 2021;27:671–686. doi:10.1016/j.cmi.2020.12.009
   Web of Science ®Google Scholar
• Vazin A, Karimzadeh I, Zand A, et al. Evaluating adherence of health-care team to standard guideline of colistin use at intensive care units of a referral hospital in Shiraz, Southwest of Iran. Adv Pharm Bull. 2017;7(3):391–397. doi:10.15171/apb.2017.047
   Web of Science ®Google Scholar
• Venkataraman R, Kellum JA. Defining acute renal failure: the RIFLE criteria. J Intensive Care Med. 2007;22(4):187–193. doi:10.1177/0885066607299510
   PubMedGoogle Scholar
• Elias LS, Konzen D, Krebs JM, et al. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother. 2010;65(10):2231–2237. doi:10.1093/jac/dkq285
   PubMed Web of Science ®Google Scholar
• Mostardeiro MM, Pereira CA, Marra AR, et al. Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients. Antimicrob Agents Chemother. 2013;57(3):1442–1446. doi:10.1128/AAC.01329-12
   Web of Science ®Google Scholar
• Rigatto MH, Behle TF, Falci DR, et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother. 2015;70(5):1552–1557. doi:10.1093/jac/dku561
   PubMed Web of Science ®Google Scholar
• Dubrovskaya Y, Prasad N, Lee Y, et al. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother. 2015;70(6):1903–1907. doi:10.1093/jac/dkv014
   PubMed Web of Science ®Google Scholar
• Tuon FF, Rigatto MH, Lopes CK, et al. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2014;43(4):349–352. doi:10.1016/j.ijantimicag.2013.12.002
   PubMed Web of Science ®Google Scholar
• Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53:879–884. doi:10.1093/cid/cir611
   PubMed Web of Science ®Google Scholar
• Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Hum Gene Ther Clin Dev. 2011;31:1257–1264. doi:10.1592/phco.31.12.1257
   Google Scholar
• Vazin A, Malek M, Karimzadeh I. Evaluation of colistin nephrotoxicity and urinary level of kidney injury molecule-1 in hospitalized adult ICU patients. J Renal Inj Prev. 2020;9(2):e13. doi:10.34172/jrip.2020.13
   Web of Science ®Google Scholar
• Akajagbor DS, Wilson SL, Shere-Wolfe KD, et al. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis. 2013;57(9):1300–1303. doi:10.1093/cid/cit453
   PubMed Web of Science ®Google Scholar
• Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014;58(5):2740–2746. doi:10.1128/AAC.02476-13
   PubMed Web of Science ®Google Scholar
• Maniara BP, Healy LE, Doan TL. Risk of nephrotoxicity associated with nonrenally adjusted intravenous polymyxin b compared to traditional dosing. J Pharm Pract. 2020;33(3):287–292. doi:10.1177/0897190018799261
   Web of Science ®Google Scholar
• Rello J, van Engelen TSR, Alp E, et al. Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect. 2018;24(12):1264–1272. doi:10.1016/j.cmi.2018.03.011
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111. doi:10.1093/cid/ciw353
   PubMed Web of Science ®Google Scholar
• Ciarambino T, Giannico OV, Campanile A, et al. Acute kidney injury and vancomycin/ piperacillin/tazobactam in adult patients: a systematic review. Intern Emerg Med. 2020;15(2):327–331. doi:10.1007/s11739-020-02287-2
   Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39. doi:10.1002/phar.2209
   PubMed Web of Science ®Google Scholar